CD19 and lymphoma: It is worth mentioning that in a retrospective study, polatuzumab vedotin in combination with rituximab has shown limited and short-lasting activity in R/R lymphoma patients after failure of anti-CD19 chimeric antigen receptor (CAR) T cell therapy [104].